At Sprint Bioscience we are very happy that a field of research that we have actively pursued for more than 5 years is now being rewarded the Nobel prize in medicine.
Sprint Bioscience is a Swedish company that since the start has been running a project for autophagy inhibition for cancer treatment. The project is targeting a key protein for autophagy initiation, Vps34. By collaborations, international and in Sweden, Sprint Bioscience has built a world class expertise within autophagy and its role in cancer. The scientific advisors of the company, Dr Ravi Amaravadi, was visiting Sweden last Friday and gave a talk on autophagy and cancer therapy, hosted by Sprint Bioscience.
“Thanks to the scientific work of Professor Ohsumi we now have an in-depth understanding of the mechanisms of autophagy, which is fundamental to our daily work in the Vps34 project”, Anders Åberg, CEO, Sprint Bioscience says.
Sprint Bioscience has, as one of few companies in the world, an active program to develop inhibitors of autophagy. “We are delighted that the Nobel Committee acknowledge that autophagy is an important process in cancer development” says Jessica Martinsson, project leader of the Vps34 project and VP Medicinal Chemistry, Sprint Bioscience.
Sprint Bioscience AB (publ) is part of the new Swedish pharmaceutical industry and has the goal to develop drug candidates for the global pharmaceutical market within the field of oncology in a more time- and resource-efficient manner. Sprint Bioscience is situated in Stockholm, Sweden. Sprint Bioscience share is listed on NASDAQ First North Premier and traded under the name SPRINT.
Additional information is available on the company website; www.sprintbioscience.com.
Certified Advisor is Erik Penser Bank, www.penser.se.
Sprint Bioscience │ Novum│141 57 Huddinge │ Sweden │ 46-(0)8-411 44 55 │email@example.com